apixaban vs prasugrel
Side-by-side comparison of apixaban and prasugrel Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Apixaban (Eliquis) is a medicine that helps prevent blood clots. It is used to lower the risk of stroke and other serious problems caused by blood clots.
Prasugrel is a drug that helps prevent blood clots. It is used to lower the risk of heart attack, stroke, and blood clots in people with acute coronary syndrome who are undergoing a procedure called percutaneous coronary intervention (PCI).
Apixaban is used to lower the chance of stroke in people with an irregular heartbeat called atrial fibrillation. It also prevents blood clots in the legs (deep vein thrombosis or DVT) that can happen after hip or knee replacement surgery. Apixaban is also used to treat DVT and lung clots (pulmonary embolism or PE), and to prevent them from coming back.
Prasugrel helps prevent dangerous blood clots if you have acute coronary syndrome. This includes unstable angina (chest pain) or a heart attack. It is for people who will have a procedure to open blocked arteries, called percutaneous coronary intervention (PCI). Prasugrel can lower your chance of heart attack, stroke, or death.
Apixaban is a type of drug called a factor Xa inhibitor. It works by blocking a substance in the blood that helps clots form. This helps to keep your blood flowing smoothly.
Prasugrel belongs to a class of drugs called P2Y12 inhibitors. It works by blocking a substance in your blood called ADP. By blocking ADP, prasugrel helps prevent platelets (blood cells that cause clotting) from sticking together and forming unwanted blood clots.
- • Bleeding more easily (like nosebleeds or heavier periods)
- • Bruising more easily
- • Bleeding
- Irregular heartbeat 3,970
- Shortness of breath 3,598
- Stroke 3,508
- Blood clot 2,806
- Using the medicine for something it's not approved for 2,693
- Heart attack 172
- Drug not working 106
- Shortness of breath 106
- Sudden heart attack 102
- Using the drug for a non-approved purpose 93
Apixaban has two important warnings. First, stopping apixaban too early can raise your risk of blood clots. Don't stop taking it without talking to your doctor. Second, if you have spinal anesthesia or a spinal puncture while taking apixaban, you could get a blood clot around your spine, which can cause long-term paralysis.
Prasugrel can cause serious bleeding, which can sometimes be fatal. You should not take this medicine if you have active bleeding or have had a stroke or transient ischemic attack (TIA). If you are 75 or older, prasugrel is generally not recommended due to the increased risk of bleeding, unless you have diabetes or have had a prior heart attack. Do not start prasugrel if you are likely to need urgent heart bypass surgery (CABG). If possible, stop taking prasugrel at least 7 days before any surgery. Other things that raise your bleeding risk are: body weight under 60 kg, a tendency to bleed easily, and taking other medicines that increase bleeding risk. If you have low blood pressure and recently had a heart procedure or surgery, suspect bleeding. If possible, manage bleeding without stopping prasugrel, because stopping it can raise your risk of heart problems.
Apixaban is not recommended during pregnancy because it may increase the risk of bleeding during pregnancy and delivery. Talk to your doctor about the risks and benefits of taking apixaban if you are breastfeeding. You may need to stop taking the drug or stop nursing.
There is not enough information about the safety of prasugrel during pregnancy. Tell your doctor if you are pregnant or plan to become pregnant. It is not known if prasugrel passes into breast milk, so talk to your doctor about the risks and benefits of breastfeeding while taking this medicine.
Also Compare — Nearby Drugs
Compare apixaban with
Compare prasugrel with
How to Read This apixaban vs prasugrel Comparison
apixaban is classified in the Direct Oral Anticoagulant (Factor Xa Inhibitor) drug class, while prasugrel sits within the P2Y12 Inhibitor (Antiplatelet) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, apixaban has 16,575 submissions while prasugrel has 579. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between apixaban and prasugrel — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.